Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RMTI 
Rockwell Medical Inc (RMTI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RMTI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.02% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 61.97M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 1.63 | 52 Weeks Range 0.78 - 5.15 | Updated Date 08/28/2025 |
52 Weeks Range 0.78 - 5.15 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.05 | Actual -0.01 |
Profitability
Profit Margin -2.39% | Operating Margin (TTM) -8.39% |
Management Effectiveness
Return on Assets (TTM) -1.53% | Return on Equity (TTM) -7.79% |
Valuation
Trailing PE - | Forward PE 59.17 | Enterprise Value 57559633 | Price to Sales(TTM) 0.7 |
Enterprise Value 57559633 | Price to Sales(TTM) 0.7 | ||
Enterprise Value to Revenue 0.53 | Enterprise Value to EBITDA 37.47 | Shares Outstanding 34430400 | Shares Floating 28266630 |
Shares Outstanding 34430400 | Shares Floating 28266630 | ||
Percent Insiders 13.71 | Percent Institutions 17.19 |
Upturn AI SWOT
Rockwell Medical Inc
Company Overview
History and Background
Rockwell Medical, founded in 1995, focuses on dialysis solutions and drug therapies for end-stage renal disease (ESRD). It has evolved from a device manufacturer to a pharmaceutical company in the dialysis space.
Core Business Areas
- Drug Products: Supplies pharmaceutical products to dialysis clinics for treating anemia, secondary hyperparathyroidism, and iron deficiency. Triferic is the main product.
- Dialysis Solutions: Manufactures and delivers hemodialysis concentrates and other ancillary products used in dialysis treatments.
Leadership and Structure
Rockwell Medical has a CEO leading a management team responsible for strategic direction and operational execution. The company is structured to manage pharmaceutical production and dialysis solutions business lines.
Top Products and Market Share
Key Offerings
- Triferic: Triferic is a soluble ferric pyrophosphate (SFP) that delivers iron to the bone marrow during hemodialysis. Used to maintain hemoglobin in dialysis patients. Market share data not readily available. Competitors include injectable iron supplements from companies like Vifor Pharma and Akebia Therapeutics(AKBA).
- Dialysis Concentrates: Solutions used in hemodialysis machines to remove waste and excess fluids from the blood. Market share data not readily available. Competitors include Baxter International (BAX) and Fresenius Medical Care (FMS).
Market Dynamics
Industry Overview
The renal dialysis market is driven by the increasing prevalence of kidney disease, aging populations, and technological advancements in dialysis treatments.
Positioning
Rockwell Medical focuses on innovating dialysis treatments and providing essential supplies to dialysis clinics. Competitive advantages lie in specialized drug therapies and integrated solutions.
Total Addressable Market (TAM)
The global dialysis market is projected to reach around $100 billion. Rockwell Medical is positioned to capture a share of the dialysis drug and concentrate segments.
Upturn SWOT Analysis
Strengths
- Specialized drug therapies (Triferic)
- Established presence in the dialysis market
- Focus on innovation in dialysis solutions
Weaknesses
- Limited product portfolio
- Dependence on a few key products
- History of financial losses
Opportunities
- Expanding the use of Triferic in different dialysis settings
- Developing new therapies for ESRD
- Strategic partnerships with dialysis clinics
Threats
- Competition from larger dialysis providers
- Pricing pressures in the dialysis market
- Regulatory changes affecting dialysis treatments
Competitors and Market Share
Key Competitors
- BAX
- FMS
- AKBA
Competitive Landscape
Rockwell Medical competes with larger dialysis providers and pharmaceutical companies. Its competitive advantage lies in its specialized products and focus on renal disease.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of revenue growth offset by losses.
Future Projections: Future growth depends on the success of Triferic and new product development.
Recent Initiatives: Recent initiatives likely include expanding the sales and marketing efforts for Triferic and seeking partnerships to improve market access.
Summary
Rockwell Medical focuses on the renal disease treatment market with a reliance on its pharmaceutical product Triferic. The company has faced financial difficulties and must compete against larger, well-established companies. Future success depends on growing Triferic sales, new product development, and strategic partnerships. Investors should be wary of the current state of the company because it is not making money.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Market Research Reports
- Press Releases
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rockwell Medical Inc
Exchange NASDAQ | Headquaters Wixom, MI, United States | ||
IPO Launch date 1998-01-27 | President, CEO & Director Dr. Mark Strobeck Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 244 | Website https://www.rockwellmed.com |
Full time employees 244 | Website https://www.rockwellmed.com | ||
Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics, including dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.